For the quarter ending 2025-09-30, LIXTW had $1,848,922 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -3,465,626 |
| General and administrative costs | 1,144,348 |
| Common stock issued for services | 44,711 |
| Unrealized gain (loss) on digital assets | -182,887 |
| Prepaid insurance | 8,592 |
| Other prepaid expenses | -23,814 |
| Accounts payable and accrued expenses | 95,661 |
| Research and development contract liabilities | 77 |
| Net cash used in operating activities | -1,982,720 |
| Purchase of digital assets | 2,637,360 |
| Net cash used in investing activities | -2,637,360 |
| Proceeds from sale of securities in registered direct offerings, net of offering costs | 2,245,040 |
| Proceeds from sale of securities in registered private placement, net of offering costs | 4,178,162 |
| Exercise of common stock warrants | 45,800 |
| Net cash provided by financing activities | 6,469,002 |
| Net increase (decrease) | 1,848,922 |
| Cash and cash equivalents at beginning of period | 1,038,952 |
| Cash and cash equivalents at end of period | 2,887,874 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)